Effect of Androgel [testosterone] on atherogenesis, inflammation, cardiovascular risk factors and adiposity in type 2 diabetic males with hypogonadotrophic hypogonadism: A prospective, randomized and controlled-study

Trial Profile

Effect of Androgel [testosterone] on atherogenesis, inflammation, cardiovascular risk factors and adiposity in type 2 diabetic males with hypogonadotrophic hypogonadism: A prospective, randomized and controlled-study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 17 Dec 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 23 Jun 2010 'Abbott Laboratories' added as trial sponsor as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top